Events & Presentations

Upcoming Events
Date Event Details Remind Me
Nov 30, 2021
Piper Sandler 33rd Annual Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Dec 2, 2021 1:00 PM EST
4th Annual Evercore ISI HealthCONx Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Dec 3, 2021
18th Global Cardiovascular Clinical Trialists Forum
James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”
Archived Events
Date Event Details
Nov 13 - Nov 17, 2020
American Heart Association (AHA) Scientific Sessions 2020

Title: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia
Authors: Gerald F. Watts, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia
Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a)
Authors: Michael J. Koren, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Nov 13 - Nov 16, 2020
The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Title: ARO-AAT Reduces Serum and Intra-hepatic Z-AAT Protein in PIZZ Alpha-1 Antitrypsin Deficient Patients with Liver Disease Leading to Improvements in Clinically Relevant Liver Biomarkers
Authors: Pavel Strnad, et al.
Publication Number: LP14
Session: Late-breaking Abstract Posters
Oct 8, 2020 8:30 AM EDT
Arrowhead/Takeda Collaboration Call
Oct 6, 2020 1:30 PM EDT
Chardan Virtual 4th Annual Genetic Medicines Conference
Vince Anzalone, CFA, Arrowhead’s vice president and head of investor relations, will participate in a fireside chat presentation
Sep 15, 2020 2:00 PM EDT
Cantor Fitzgerald Global Healthcare Conference 2020
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Sep 15, 2020 9:30 AM EDT
H.C. Wainwright 22nd Annual Global Investment Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Sep 10, 2020 2:00 PM EDT
Baird's 2020 Global Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Sep 9, 2020
Citi’s 15th Annual BioPharma Virtual Conference
Aug 29 - Sep 1, 2020
European Society of Cardiology (ESC) Congress 2020
Title: RNA Interference Targeting Apolipoprotein C-3 with ARO-APOC3 in Healthy Volunteers Mimics Lipid and Lipoprotein Findings Seen in Subjects With Inherited Apolipoprotein C-3 Deficiency
Authors: Christian Schwabe, et al.
Presenter: Christie M. Ballantyne
Date and Time: August 31, 2020 at 10:50 CEST

Title: RNAi Inhibition of Angiopoietin-like Protein 3 (ANGPTL3) with ARO-ANG3 Mimics the Lipid and Lipoprotein Profile of Familial Combined Hypolipidemia
Authors: Gerald F. Watts, et al.
Date and Time: August 31, 2020 at 11:00 CEST
Aug 27 - Aug 29, 2020
The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver (EASL)
Title: Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Authors: Edward Gane, et al.